Zynerba Pharmaceuticals, Inc. (ZYNE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
80 West Lancaster Avenue
Devon, PA 19333
United States of America (the)
Phone
484 581 7505
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
25
First IPO Date
August 05, 2015
| Name | Title | Pay | Year Born |
| James E. Fickenscher | Chief Financial Officer & Vice President of Corporation Devel. (Leave of Absence) | 607,622 | 1964 |
| Kenneth T. Jones | Vice President, Corporation Controller & Interim Chief Financial Officer | 0 | 1964 |
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.